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The  aim  of this  study  was to  evaluate  small  doses  of known  cytochrome  P450  enzyme
inhibitors,  grapefruit  juice  (GFJ)  and one  of  its components,  bergamottin  (BGT),  for  the
prevention  of paracetamol  (PAR)-induced  hepatotoxicity  after  overdose  in  rats. Six groups
of 15  Sprague  Dawley  (SD)  rats  each  were  treated  with  single  oral  doses  of  either  saline,
PAR only  1725  mg/kg,  PAR + GFJ  low  dose  (2  ml)  and  PAR  + GFJ  high  dose  (3 ml),  PAR  +  BGT
0.05  mg/kg  (BGT-low)  and  PAR  +  BGT 0.22  mg/kg  (BGT-high).  Thereafter,  5 rats  from  each
group  were  sacriﬁced  after  24,  48 and  72 h  and,  on each  occasion,  blood  samples  were
collected  for  determination  of  liver  and renal  function,  full blood  count  (FBC)  and PAR
concentration.  A piece  of liver  was  sent  for histopathology.  By  48  h  the  liver enzymes  in
the  PAR-only  group  were  signiﬁcantly  (P < 0.05)  higher  than  in the  PAR  +  GFJ  and  PAR  +  BGT
groups,  i.e.,  alanine  transaminase  (ALT)  837  ±  268  u/L  and  aspertate  transaminase  (AST)
1359  ± 405  for  PAR only;  versus  ALT 34  ±  48.8  u/L  and  AST  238  ± 221  for  PAR  +  GFJ-high;  ALT
22  ± 13.9  and  AST168  ± 49.6  for  PAR  + BGT-high;  and  ALT  52 ± 7.2 u/L  and  AST  147  ±  153 for
the  control  group.  The  results  correlated  with  the  histopathology  ﬁndings  where  livers  of
the PAR-only  group  exhibited  severe  centrilobular  and  hepatocyte  necrosis.  In conclusion,
GFJ  and BGT  prevented  PAR-induced  hepatotoxicity  after  PAR  overdose  in  rats, and  this
calls  for  appropriate  observation  studies  in humans.
© 2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
. Introduction
PAR is a widely used analgesic and antipyretic agent.
hile it is generally safe at recommended doses, acute
verdose of PAR can cause fatal liver damage [1,2].
fter PAR overdose, the major metabolic pathways of
lucuronidation and sulphation become saturated and
he excess PAR is bioactivated by cytochrome P450
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isoenzymes to a hepatotoxic metabolite, N-acetyl-p-
benzoquinoneimine (NAPQI) [3]. Currently, N-acetyl-
cysteine (NAC) is the drug of choice for treating PAR
overdose. It converts the NAPQI to non-toxic cysteine and
mercaptate conjugates. Unfortunately, the use of NAC is
hampered by uncertainty on outcome in relation to the
time and route of administration, the fact NAC does not stop
the production of NAPQI and the fear for hypersensitivity
reactions. On the other hand, despite the understanding
that some cytochrome P450 isoforms are responsible for
activation of PAR to NAPQI, the use of enzyme inhibitors
for prevention and/or treatment of PAR-induced hepato-
toxicity is still not well researched. In a previous report
by Walubo and co-workers [4], it was  demonstrated that
is is an open access article under the CC BY-NC-ND license
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administration of a hepatotoxic dose of PAR in combina-
tion with known inhibitors of cytochrome P450 3A4, 2E1
and 1A2, i.e.,  ketoconazole, isoniazid and caffeine, pre-
vented the development of PAR-induced hepatotoxicity.
Unfortunately, because of their side effects and therapeu-
tic use, these drugs could not be investigated further for
treatment or prevention of PAR-induced hepatotoxicity. As
such, there was a need to search for appropriate candidates
for use in the prevention PAR hepatotoxicity.
Although GFJ interaction with cytochrome P450 had
been known for some time, it was only recently that
furanocoumarins were identiﬁed as the mediators of the
interaction between GFJ and CYP3A4 [5,6]. Generally furan-
ocoumarins are well known plant phytotoxins believed
to serve as the plants’ defense mechanism against preda-
tors. However, some furanocoumarin-monomers found in
the GFJ such as BGT (GF-I-2), 6′,7′-dihydroxybergamottin
(DHB), and dimers such as paradisine A (GF-I-1) and para-
disine B (GF-I-4) are suitable for human consumption [7,8].
In this perspective, along with the wide availability of GFJ,
it was found more attractive to evaluate GFJ or extract for
prevention of PAR hepatotoxicity. Therefore, the aim of
the study was to evaluate GFJ and one of its component
furanocoumarins, BGT, for the prevention of PAR-induced
hepatotoxicity after overdose in rats.
2. Materials and methods
2.1. Materials and apparatuses
PAR syrup and tablets were purchased from a local
pharmacy; pure acetaminophen powder and BGT were
purchased from Sigma–AldrichTM (St. Louis, MO,  USA),
while grapefruits (Star Ruby) were bought from a local
super market. The rounded end needles (16 G-3′′, curved
3.00 mm ball) used for oral gavage feeding were purchased
from Popper & Sons, New York. The human cytochrome
P450 (Bacculosomes®, InvitrogenTM, Carlsbad, CA, USA)
were used to screen GFJ extract for enzyme inhibition.
2.2. Preliminary experiments
2.2.1. Preparation of grapefruit extracts
Fifty (50) Star Ruby grapefruits were peeled, and the
peels were homogenised for 2 min  using a food blender,
during which 1000 ml  of distilled water was added. The
homogenate was ﬁltered to remove the pulp, after which
it was centrifuged for 15 min  at 11,963 × g (10,000 r.p.m.).
The supernatant was extracted with 2.5 volumes of ethyl
acetate, shaken vigorously and centrifuged for 15 min. The
aqueous phase was removed and the organic layer evap-
orated using a rotary evaporator at 45 ◦C. The residue (or
oily peel extract) was weighed, reconstituted with water,
and stored at −20 ◦C until analysis. The juice was squeezed
from the grapefruit by hand, after which it was ﬁltered and
centrifuged for 5 min  at 7026 × g (13,400 r.p.m.) and stored
at 4 ◦C until analysis. Of note, furanocoumarins content in
juices stored for up to 20 weeks at 4 ◦C remained fairly
constant [9].orts 2 (2015) 677–684
2.2.2. HPLC assay
The two  grapefruit products were characterised by qual-
itative HPLC screening for furanocoumarins using BGT as
the standard. 100 l of the peel-extract was centrifuged at
7026 × g (13,400 r.p.m.) for 5 min  and 20 l of the super-
natant was injected into the HPLC. The juice was also
centrifuged at 7026 × g (13,400 r.p.m.) for 5 min  and the
supernatant (100 l) was directly injected into the HPLC.
BGT stock solution in acetonitrile was  diluted with the
mobile phase to 100 g/ml.
The HPLC system was  a Hewlett Packard model
1100 that was  equipped with an autosampler (Wald-
bronn, Germany), and UV detector (Shimadzu, Tokyo,
Japan). The mobile phase comprised of Solvent A and
B. Solvent A consisted of 10% acetonitrile in TEAP
buffer, whereas Solvent B was 0.01% sulphuric acid
in acetonitrile. TEAP buffer was prepared by mixing
phosphoric acid (2.9 g) with 15.54 g of tetraethylammo-
niumhydroxide (TEAH) in 500 ml  distilled water. The
chromatographic conditions consisted of a Phenomenex®
C18 column (150 mm × 4.60 mm,  3 m particle size), cou-
pled to a SecurityGuardTM C18 (4 mm × 3 mm)  guard
column (Phenomenex®, Torrance, CA, USA), with a mobile
phase (30% A) ﬂow rate of 1.0 ml/min and a UV detector set
at 210 nm.
Under these conditions, BGT was  eluted at 18 min
(Fig. 1a), and this retention time was  similar to a peak in the
GFJ at 17 min  (Fig. 2a) and UV spectrum (Figs. 1b and 2b).
Although the peel extract exhibited many peaks, there was
no signiﬁcant peak between 14 and 20 min. Therefore, the
peel extract was  not processed any further.
2.2.3. Cytochrome P450 activity
The grapefruit juice was  further evaluated to determine
if it had cytochrome P450 enzyme inhibitor properties
required for the product to be used in the prevention
of PAR hepatotoxicity. GFJ was screened for its effect
on the activities of human CYP2E1, CYP3A4 and CYP1A2
in vitro, the isoforms implicated in the activation of PAR
to a toxic metabolite. The effect of GFJ on the activ-
ity of a speciﬁc P450-isoform was tested by observing
for changes in the rate of metabolism with the addi-
tion of increasing amount (0, 5, 10, 15, 20 l; n = 5) of
the GFJ to the reaction mixture (250 l, with phosphate
buffer pH 7.4). This was  done separately for each of the
following P450-isoforms: CYP3A4, CYP1A2, and CYP2E1.
The rate of metabolism for CYP3A4 was determined by
monitoring for the rate of 4-hydroxylation of midazo-
lam (0.25 mM),  while for CYP2E1 was by 4-hydroxylation
chlorzoxazone (2 mM),  and CYP1A2 by O-dealkylation of 7-
ethoxyresoruﬁn (0.1 mM).  GFJ inhibited the activity of each
enzyme with increasing concentration of GFJ (Fig. 3).
2.3. The main experiment
2.3.1. Animal care
The study was approved by the Animal Ethics Com-mittee of the University of the Free State (NR 10/2012).
Sprague-Dawley (SD) rats weighing between 200 and 250 g
were used. Animals were kept and treated at the Animal
House of the University. Here they were fed and looked
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Fig. 1. (a) A chromatogram of bergamottin (Peak A) in standard in mobile phase. (b) A UV spectrum of Peak A (bergamottin).
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Fig. 2. (a) A chromatogram of grapefruit juice (un-extracted) with several peaks. Peak C has similar retention time to bergamottin (Fig. 1a). (b) A
chromatogram of the UV spectrum of peak C in grapefruit juice is similar to that of bergamottin (Fig. 1b).
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Standard rat chow and water was available ad libitum. All
animals were inspected for any abnormal signs every day.
2.3.2. Determination of the toxic dose of PAR
A preliminary experiment to determine a dose of PAR
that would induce hepatotoxicity was conducted. Hep-
atotoxicity was diagnosed when the liver enzymes, ALT
increased above 5-fold that of the control animal (note; ani-
mal  care was as described later). Three groups of 9 SD rats
(200–250 g) each were treated with a single dose of either
1000, 1725 or 1822 mg/kg of PAR and, from each group, 3
rats were sacriﬁced after 24, 48 and 72 h after dosing. One
group of 3 rats was not treated. Blood was tested for FBC,
LFT and RFT.
There was no change in liver enzymes on the three occa-
sions after 1000 mg  dose. At 48 h, elevated liver enzymes
were observed after 1725 mg/kg dose (ALT 837 (647–1026),
AST 1359 (1073–1645) and ALP 296 (191–401)), and after
1822 mg/kg dose (ALT 449 (64–728), AST 1201 (156–1651)
and ALP 231 (153–364)). Whereas after 72 h the liver
enzymes in the 1725 mg/kg group remained high (ALT
419.0 ± 586, AST 512.0 ± 593, ALP 260.0 ± 36), they fell
far lower in the 1822 mg/kg group (ALT 44.3 ± 3, AST
104.0 ± 14, ALP 223.7 ± 82) most probably due to cell death.
Since the 1725 mg/kg group exhibited hepatotoxicity that
was sustained over the study period, it was selected for use
in the subsequent experiments.
2.3.3. Experimental design
Rats were divided into ﬁve groups of 15 animals each
and were administered orally with either 1 ml of saline
(Saline) or 2 ml  GFJ (GFJ-low) or 3 ml  GFJ (GFJ-high) or
0.05 mg/kg BGT (BGT-low) or 0.22 mg/kg BGT (BGT-high),
and ﬁve rats from each group were sacriﬁced after 24,
48 and 72 h. Another ﬁve groups of 15 animals each
were also administered orally but with either 1725 mg/kg
PAR (PAR) or 1725 mg/kg PAR and 2 ml  GFJ (PAR + GFJ-
low) or 1725 mg/kg PAR and 3 ml  GFJ (PAR + GFJ-high) or
1725 mg/kg PAR and 0.05 mg/kg BGT (PAR + BGT-low) or
1725 mg/kg PAR and 0.22 mg/kg BGT (PAR + BGT-high), and
ﬁve rats from each group were sacriﬁced after 24, 48 and
72 h. Except where indicated, the respective doses of BGTP1A2, CYP2E1 and CYP3A4 in vitro [PAR was added to mimic the clinical
 = 5].
and PAR were dissolved in 1 ml  of saline as ordered by the
animal ethics committee.
2.3.4. Blood collection and surgical procedure
Under isoﬂurane anaesthesia, blood (5 ml)  was drawn
by cardiac puncture and immediately aliquoted to the
appropriate test tubes. Thereafter, the abdomen was
opened through a vertical incision to expose the liver. A
piece of liver (10 g) was cut and stored in 10% formalin
and sent for histopathology. The remainder of the liver was
quickly dissected out, washed in a 1.5% potassium chloride
solution, frozen with liquid nitrogen and stored at −85 ◦C.
Thereafter, the animals were sacriﬁced by exsanguination
whilst still under anaesthesia. PAR concentrations were
measured in our laboratory using a validated HPLC method.
The full blood count, liver and renal function tests were
done at the National Health Laboratory System (NHLS;
Bloemfontein, South Africa), while histopathology of the
livers was performed and reported by an independent
veterinary pathologist (Idexx Laboratories, Johannesburg,
South Africa).
2.3.5. PAR HPLC assay
PAR concentrations were measured in rat plasma by
HPLC. It involved protein precipitation of 50 l of rat
plasma with 30 l 2.5% zinc sulphate after addition the
internal standard (4-aminoacetophenone), followed by
centrifugation. The supernatant was  directly injected into
the HPLC. The HPLC system was  an Agilent, Hewlett Packard
1100 series, equipped with a 1260 Inﬁnity quaternary
pump (Waldbronn, Germany) with a 1260 Inﬁnity degasser
attached to a G1313A autosampler (Waldbronn, Germany),
and a G1314A UV wavelength detector (Tokyo, Japan). Sep-
aration of PAR and 4-aminoacetophenone was  achieved by
running the mobile phase at a ﬂow rate of 1 ml/min. over
a Phenomenex® C18 (4.60 mm × 250 mm)  5 m analytical
column, coupled to a Phenomenex® SecurityGuardTM C18
(4 mm × 3 mm)  guard column (Torrance, CA, USA). Com-
pounds were detected by UV at a wavelength of 240 nm.
The mobile phase consisted of 0.01% triﬂuoroacetic acid
in distilled water (solvent A) and 100% HPLC grade ace-
tonitrile (solvent B), and was run isocratically (80:20, v/v).
Under these conditions, PAR was eluted at 4.25 min  and
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S at 6.25 min. The method was linear (y = 0.603x + 0.089;
2 = 0.9957; n = 5) and the limit of detection was 0.1 g/ml.
.3.6. Statistical analysis
Data was analysed by non-parametric methods using
he GraphPad Instat statistical programme and the
ann–Whitney Test was used for data comparison with
he level of signiﬁcance set at P < 0.05.
. Results
Daily animal observations did not reveal any abnormal
linical signs. The FBC, liver and renal functions tests for
he groups treated with GFJ and BGT alone were normal at
ll doses (not shown), implying that these agents did not
ause hepatotoxicity at the respective doses.
Table 1 shows the changes in liver function tests over
he 72 h following administration of PAR. There was a sig-
iﬁcant increase in the liver function tests (ALT and AST)
n the rats that were treated with PAR-only by 24 and
8 h. The increase was more than 5 times those of the
ontrol group (saline) which indicated that the PAR-only
roup had experienced hepatotoxicity. When PAR was  co-
dministered with grapefruit juice, remarkably low liver
nzyme levels (ALT and AST) were observed at 48 and 72 h.
imilarly, co-administration of PAR with BGT prevented the
ncrease in liver enzymes after 48 and 72 h. Of note, GFJ
nd BGT co-administration were associated with high PAR
oncentrations at 24 h followed by a rapid drop thereafter
Fig. 4).
During surgery, direct observation of the organs, the liv-
rs of the rats that were treated with PAR only (PAR-only)
ere highly discoloured with some exhibiting goose bump
ike spots which were most severe after 48 h of treatment,
nd still present after 72 h. The livers and kidneys of rats
reated with PAR + GFJ and PAR + BGT were normal at all
oses with a few showing a slight spotting and discoloura-
ion after 48 h, which had recovered after 72 h. Fig. 5 shows
he representative sections of the livers with the respective
istopathology reports. PAR alone caused severe hepato-
oxicity that was marked with severe centrilobular and
epatocyte necrosis at 48 and 72 h (Fig. 5 slides B & C),
hile co-administration with GFJ and BGT prevented this
o occur (Fig. 5 slides E & F, and slides H & I, respectively).
s expected from clinical observations, PAR hepatotoxicity
as not evident at 24 h.
Table 2 illustrates the changes in the full blood count
fter 24, 48 and 72 h of drug administration. In all test
nimals, PAR was associated with thrombocytopenia (low
latelet count) that was moderate in the groups treated
ith GFJ and BGT. The rest of the full blood count parame-
ers were not affected.
Pathology reports
Fig. 5 shows sections of a rat livers from groups treated
ith: single toxic dose of PAR-only (A, B, C); PAR + GFJ (D,
, F); and PAR + BGT (G, H, I) as follows:A: 24 h after dosing with PAR.
◦ The section of liver reveals mild granular vacuolar
degeneration and very mild swelling of the hepato-
cytes. The trabecular structure can still be visualised, asorts 2 (2015) 677–684 681
can the sinusoids, although slightly reduced in diame-
ter. There is a mild mononuclear portal inﬂammatory
inﬁltrate mainly composed of macrophages.
• B: 48 h after dosing with PAR.
◦ Under low power (4× magniﬁcation) severe centrilob-
ular bridging necrosis can be seen. Large conﬂuent
areas of necrosis characterised by loss of hepato-
cyte nuclei, disarrangement of the cords and loss of
structure is present in the centrilobular areas, with
extension from the centrilobular regions through the
zones to link up with other centrilobular areas. The
hepatocytes are lightly eosinophilic and there is loss
of the trabecular structure and the acute necrosis is
associated with mild haemorrhage as well as acute
inﬂammatory cells including polymorphonuclear cells
and mononuclear cells. The rest of the hepatocytes
between the bridging necrosis reveal mild to moderate,
granular, vacuolar degeneration and mild fatty change.
• C: 72 h after dosing with PAR.
◦ Severe centrilobular bridging necrosis with severe cen-
trilobular and periportal inﬂammation characterised
by mononuclear inﬂammatory cells. The bridging
necrosis is similar to that already described, charac-
terised by eosinophilia of the hepatocytes with loss of
nuclei and trabecular structure. Increased mitotic ﬁg-
ures at approximately four mitoses per high power ﬁeld
(40× magniﬁcation) can be seen close to the necrotic
zones, but within the preserved areas. Some of the
necrotic areas maintain an outline of the hepatocytes,
suggesting acute coagulative necrosis. There is a mild
leukostasis.
• D: 24 h after dosing with PAR + GFJ (3 ml):
◦ Mild vacuolar change and swelling, mild leukostasis
and reduced numbers of mitoses. Mild portal mono-
nuclear inﬂammatory inﬁltration.
• E: 48 h after dosing with PAR + GFJ (3 ml):
◦ Mild to moderate vacuolar change and degeneration
with mild, portal, mononuclear inﬂammatory inﬁl-
trates and very few mitotic ﬁgures.
• F: 72 h after dosing with PAR + GFJ (3 ml):
◦ with few mitotic ﬁgures and mononuclear inﬂamma-
tory inﬁltration.
• G: 24 h after dosing with PAR + BGT (0.22 mg/kg):
◦ Moderate to severe vacuolar degeneration and severe
swelling of the hepatocytes with a mild mononuclear
portal cell inﬁltration.
• H: 48 h after dosing with PAR + BGT (0.22 mg/kg):
◦ Moderate vacuolar degeneration and mild mono-
nuclear portal inﬁltration with few mitoses.
• I: 72 h after dosing with PAR + BGT (0.22 mg/kg):
◦ Severe vacuolar degeneration and swelling of the hepa-
tocytes with loss of trabecular structure and odd, small
granules of bile pigment could be seen within the hepa-
tocytes and sinusoids.
4. DiscussionThis study has illustrated that GFJ and BGT can protect
against PAR-induced hepatotoxicity during PAR overdose
in rats and in a dose dependent manner. The mecha-
nism is most probably due to prevention of the metabolic
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Table 1
The liver function tests (mean ± SD) and paracetamol plasma concentrations (median & range) during the 72 h.
Group (n = 5) Weight before Rx Liver function tests (units/l) PARA conc. (g/ml)
ALP ALT AST
SAL (control)
24 h 223 ± 6.9 226 ± 45.2 44 ± 10.6 60 ± 10.6 NA
48  h 217 ± 12.7 366 ± 11.2 52 ± 7.2 147 ± 153.3 NA
72  h 214 ± 16.5 136 ± 88.7 39 ± 0.7 54 ± 2.8 NA
PAR-only
24  h 242 ± 1.6 319 ± 2.1 63 ± 41.3 156 ± 76.2 5.72 (4.38–28.15)
48  h 223 ± 4.1 296 ± 148.5 837 ± 268.0 1359 ± 404.5 4.45 (2.23–6.67)
72  h 234 ± 11.0 267 ± 38.9 419 ± 690.1 512 ± 657.9 2.02 (1.61–15.34)
PAR  + GFJ low
24 h 242 ± 6.4 62 ± 64.7 9 ± 2.5 69 ± 5.0 7.31 (6.18–10.05)
48  h 206 ± 6.5 312 ± 72.3 628 ± 764.5 641 ± 660.7 3.72 (2.07–4.01)
72  h 204 ± 3.5 285 ± 102.9 5 ± 2.8 85 ± 43.8 0.13 (0.00–0.14)
PAR  + GFJ high
24 h 227 ± 12.9 212 ± 114.1 18 ± 7.6 141 ± 65.8 12.87(3.99–18.81)
48  h 207 ± 6.5 222 ± 34.0 34 ± 48.8 238 ± 220.5 0.92 (0.92–1.42)
72  h 215 ± 18.0 327 ± 34.6 27 ± 26.1 147 ± 52.4 1.14 (0.99–1.67)
PAR  + BGT low
24 h 208 ± 5.1 194 ± 86.0 9 ± 3.0 94 ± 45.6 4.90 (3.77–11.28)
48  h 221 ± 7.2 156 ± 104.6 17 ± 13.1 81 ± 7.0 0.84 (0.49–2.43)
72  h 205 ± 1.5 283 ± 74.8 12 ± 7.1 83 ± 18.6 0.84 (0.49–2.43)
PAR  + BGT high
24 h 207 ± 7.5 268 ± 48.4 9 ± 4.4 104 ± 9.2 7.78 (6.84–8.66)
48  h 212 ± 4.6 314 ± 36.8 22 ± 13.9 168 ± 49.6 5.57 (5.26–16.93)
sferase;72  h 218 ± 8.1 237 ± 18.6 
Rx = treatment; ALP = alkaline phosphatase; ALT = alanine aminotran
GFJ  = grapefruit juice; BGT = bergamottin.
activation of PAR by inhibition of cytochrome P450. BGT
was selected for use in this study because it was  commer-
cially available and, is considered safe to use in humans, as
indicated by their use in several human drug-disposition
studies where they were given at dosages up to 35 mol
[8,10]. Indeed, several compounds in the GFJ were demon-
strated to be potent inhibitors of P450 enzymes CYP1A2,
CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and the enzyme
inhibition was related to total furanocoumarin content
whereby no single furanocoumarin could be marked as the
sole cause [7,11]. Moreover, the furanocoumarin dimers,
paradisine A (GF-I-1) and paradisine B (GF-I-4), were more
potent enzyme inhibitors than the monomers, BGT (GF-I-
2; over 100 times) and 6-7-dihydroxybergamottin (DHB;
Fig. 4. Paracetamol plasma concentrations in the PAR-only12 ± 7.6 110 ± 38.2 0.13 (0.00–0.16)
 AST = aspartate aminotransferase; PAR = paracetamol; SAL = saline;
over 20 times) [7]. In general, further characterisation of
the GFJ for furanocoumarins would not be conclusive given
that more new furanocoumarins have been indentiﬁed in
GFJ and their standards are not yet available to aid their
analysis [12]. Therefore, for this study, it was sufﬁcient to
establish that the GFJ used had enzyme inhibitor properties
for the three CYP450 isoforms implicated in the metabolic
activation of PAR. A faster drop in PAR concentrations in
the GFJ and BGT groups than in the PAR-only group was
most probably due to a better functioning of their livers
(metabolism and/anti-oxidant) in these groups, compared
to the damaged liver of the PAR-only group.
Because of wide interspecies variations in sensitivity to
PAR hepatotoxicity, whereby rats in particular are more
, PAR + GFJ and PAR + BGT groups at 24, 48 and 72 h.
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Fig. 5. Representative histopathology slides (4×)  of rat livers at different times at different times since dosing with the respective drugs (A = 4 h, B = 48 h
and  C = 72 h after dosing with PAR; D = 24 h, E = 48 h and F = 72 h after dosing with PAR + GFJ; and G = 24 h, H = 48 h and I = 72 h after dosing with PAR + BGT).
See  the text for the corresponding pathology reports.
Table 2
Haematology results (full blood count; mean ± SD) during the 72 h after drug administration.
Group (n = 3) Full blood count
WCC  RCC Hb Hct MCV  MCH  MCHC Plt
SAL (control)
24 h 4.8 ± 0 6.2 ± 0 13.3 ± 0 0.388 ± 0 62.2 ± 2 21.1 ± 0 33.9 ± 1 970 ± 129
48  h 6.0 ± 0 6.3 ± 0 12.9 ± 1 0.387 ± 0 61.8 ± 1 20.6 ± 0 33.4 ± 1 1023 ± 162
72  h 4.9 ± 1 6.5 ± 0 13.0 ± 0 0.392 ± 0 60.5 ± 0 20.1 ± 0 33.3 ± 1 957 ± 88
PAR-only
24  h 4.1 ± 1 7.6 ± 0 15.2 ± 0 0.439 ± 0 57.6 ± 1 19.9 ± 0 34.5 ± 0 1159 ± 81
48  h 5.9 ± 0 7.5 ± 0 15.3 ± 1 0.464 ± 0 61.1 ± 1 20.4 ± 0 33.1 ± 0 310 ± 305
72  h 4.7 ± 1 6.8 ± 1 13.6 ± 2 0.406 ± 0 58.9 ± 4 19.8 ± 1 33.7 ± 1 326 ± 293
PAR  + GFJ low
24 h 6.4 ± 1 6.7 ± 0 13.4 ± 1 0.397 ± 0 59.6 ± 1 20.0 ± 1 33.6 ± 0 1101 ± 172
48  h 5.1 ± 1 6.1 ± 1 12.8 ± 3 0.387 ± 0 63.4 ± 1 20.9 ± 0 33.0 ± 0 333 ± 78
72  h 6.1 ± 1 6.2 ± 1 12.4 ± 1 0.389 ± 0 62.3 ± 1 19.8 ± 0 31.9 ± 0 627 ± 59
PAR  + GFJ high
24 h 6.2 ± 2 6.6 ± 0 13.7 ± 1 0.405 ± 0 61.0 ± 1 20.6 ± 0 33.7 ± 0 1088 ± 85
48  h 4.7 ± 1 6.1 ± 0 13.0 ± 1 0.395 ± 0 64.5 ± 1 21.2 ± 1 33.0 ± 0 464 ± 74
72  h 6.7 ± 0 6.6 ± 0 13.1 ± 0 0.399 ± 0 64.9 ± 2 21.3 ± 2 32.8 ± 0 492 ± 163
PAR  + BGT low
24 h 4.5 ± 0 5.8 ± 0 11.6 ± 1 0.353 ± 0 61.0 ± 3 20.1 ± 1 33.0 ± 0 944 ± 185
48  h 6.5 ± 0 6.4 ± 1 13.5 ± 2 0.420 ± 0 65.6 ± 2 21.0 ± 0 32.0 ± 0 587 ± 134
72  h 5.4 ± 1 6.2 ± 1 12.8 ± 1 0.380 ± 0 61.6 ± 0 20.7 ± 0 33.6 ± 0 1065 ± 122
PAR  + BGT high
24 h 7.0 ± 1 5.9 ± 1 12.4 ± 2 0.382 ± 0 64.4 ± 1 20.8 ± 1 30.6 ± 1 923 ± 68
48  h 6.6 ± 1 6.4 ± 1 13.5 ± 1 0.392 ± 0 61.7 ± 3 21.1 ± 1 34.2 ± 1 773 ± 25
72  h 5.6 ± 1 6.7 ± 1 13.5 ± 1 0.415 ± 0 62.3 ± 3 20.3 ± 1 32.6 ± 0 780 ± 119
PAR = paracetamol; GFJ = grapefruit juice; BGT = bergamottin; WCC  = white cell count; RCC = red cell count, Hb = Haemoglobin; Hct = Haematocrit;
MCV = mean corpuscular volume; MCH  = mean corpuscular haemoglobin; MCHC = mean corpuscular haemoglobin concentration; Plt = platelets.
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resistant to PAR toxicity, instead of using doses from pre-
vious studies, a toxic dose of PAR for this study was ﬁrst
established before the subsequent testing. Nevertheless,
histopathologial lesions of PAR hepatotoxicity (centrilobu-
lar necrosis) were similar to those reported in other species
including humans.
The essence of this study was to illustrate that co-
administration of a small dose of an enzyme inhibitor
such as GFJ and BGT with a toxic dose of PAR can pre-
vent development of PAR-induced hepatotoxicity in rats,
thereby opening avenues for further evaluation of these
compounds in this regard. Since most patients with PAR
overdose almost always arrive at hospital long after the
ingestion, it was envisaged that the best way to prevent
development of the hepatotoxicity is by ensuring that
patients take the PAR together with the antidote (enzyme
inhibitor). This can be achieved by addition of a small
quantity of the enzyme-inhibitor to each PAR tablet. At
normal doses, the small quantity of the enzyme-inhibitor
in each tablet would not inhibit or interfere with enzyme
activity, but when a patient takes an overdose or many
tablets that are potentially hepatotoxic, the total amount
of the enzyme-inhibitor would be high enough to inhibit
cytochrome P450 enzymes and prevent the hepatotoxic-
ity. Speciﬁcally, given that the hepatotoxic dose of PAR in
humans is 100 mg/kg, a 70 kg man  would need 15 tablets
of 500 mg  PAR each to induce hepatotoxicity. This patient
would require 15.4 mg  of BGT (0.22 mg/kg) to prevent
development of PAR heptotoxicity. It would therefore be
plausible to impregnate each PAR tablet with at least 1 mg
of BGT.
As indicated earlier, PAR is useful drug, yet it is a com-
mon  cause of drug-induced hepatotoxicity [1,2]. Currently,
owing to the fear of NAC-induced hypersensitivity reac-
tions, NAC is only recommended for patients who have
ingested a potentially hepatotoxic dose of PAR. Unfortu-
nately, the actual PAR dose or number of tablets taken is not
known in the majority of patients. Worse still, in the clin-
ical setting, clinical hepatotoxicity is only detectable after
24–48 h when liver enzymes are high, and this, together
with the fact that NAC is most useful when given in ﬁrst 8 h,
makes management of PAR overdose difﬁcult [13]. The use
of a normogram not only requires PAR concentration mea-
surements which are not available in most clinical settings,
but also makes treatment more expensive. In this study,
fresh GFJ was  preferred for testing because it is readily
available and would not need prescriptions for adminis-
tration. Using GFJ would not only obviate all the problems
with NAC enumerated above, but also reduce morbidity,
mortality and save money. The exact quantities cannot be
deduced from these animal studies, but even a low concen-
tration of GFJ (2.5% solution of GFJ) was shown to inhibit
P450 enzyme activity by 60% [11]. Since toxicology studies
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may  not be possible in humans, there is a need for further
investigations in other animals and clinical observations in
humans to enable appropriate clinical application.
In conclusion, the results of this study demonstrate that
GFJ and BGT can prevent PAR-induced hepatotoxicity.
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